Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ELI LILLY & CoLLY · Entity 2794 | SVP&Pres, LillyDiab & LillyUSA | February 04, 2019 | February 20, 2019 |
| KYNTRA BIO, INC.FGEN · Entity 7431 | Director · Chief Executive Officer | July 07, 2023 | July 10, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ELI LILLY & Co
Report date February 04, 2019 · Filed February 20, 2019 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 157,962 |
Reported balance
After 2019-02-04 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2019-02-04 · Grant · Acquired 26,682 · Balance 157,962 F1: This amendment is being filed to correctly report the amount acquired in column 4, and to correct the number of securities beneficially owned following the reported transaction, as reported in column 5. |
Filing footnotes · ownership attribution and instrument terms
F1: This amendment is being filed to correctly report the amount acquired in column 4, and to correct the number of securities beneficially owned following the reported transaction, as reported in column 5.
KYNTRA BIO, INC.
Report date July 07, 2023 · Filed July 10, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 374,722 |
Reported balance
After 2023-07-07 transaction · row 1
1 source rowRow 1 · 2023-07-07 · Sale · Disposed 1,880 · Balance 374,722 F1: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 27,800 |
Reported balance
Holding disclosure · report date 2023-07-07 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 27,800 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 26, 2012 Filed Jan 30, 2012 22:13 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 31,768 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-006122 · doc4.xml · derivative · entry 3 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,768 Underlying: Common Stock · 31,768 shares Expires 2013-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 26, 2012 Filed Jan 30, 2012 22:13 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 7,117 | $39.44 | $280,694.48 |
DisclosureSEC source: 0001209191-12-006122 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,012 Read SEC document |
| January 25, 2011 Filed Jan 27, 2011 22:53 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 19,657 | $34.73 | $682,687.61 |
DisclosureSEC source: 0001209191-11-005316 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,895 Read SEC document |
| October 18, 2010 Filed Oct 19, 2010 18:51 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 2,489 | $37.76 | $93,984.64 |
DisclosureSEC source: 0001209191-10-050887 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,238 Read SEC document |
| January 26, 2010 Filed Jan 28, 2010 23:05 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 18,335 | $36.16 | $662,993.60 |
DisclosureSEC source: 0001209191-10-005335 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Diabetes BU 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,727 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.